ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (March 4, 2020)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report March 4, 2020, filed under Item 1.01, Entry Into a Material Definitive Agreement. It states that on March 4, 2020 the company was awarded a grant from the Singapore Economic Development Board, or EDB, to support the co-development of a COVID-19 vaccine with the National University of Singapore. A portion of the Grant will be paid by the EDB in advance and the remainder incrementally upon the achievement of certain milestones related to the progress of the vaccine's development. The company has agreed to pay the EDB a royalty based on annual net sales of the vaccine in markets or jurisdictions outside of Singapore. Exhibit 99.1 is a press release dated March 4, 2020, and the signature block shows /s/ Joseph E. Payne, Chief Executive Officer.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event
reported): March 4, 2020

ARCTURUS THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified
in its charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive, Suite 250

San Diego, California 92121

(Address of principal executive offices)

Registrant’s telephone number,
including area code: (858) 900-2660

(Former name or former address, if changed
since last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry Into a Material Definitive Agreement.

On March 4, 2020, Arcturus Therapeutics
Holdings Inc. (the “Company”) was awarded a grant (the “Grant”) from the Singapore Economic Development
Board, or EDB, to support the co-development of a COVID-19 vaccine with the National University of Singapore. The grant provides
for up to S$14,039,000 million (approximately US$10 million using the March 4, 2020 exchange rate) in grants to support the development
of the vaccine.

A portion of the Grant will be paid by
the EDB in advance and the remainder of the Grant will be paid to the Company incrementally upon the achievement of certain milestones
related to the progress of the development of the vaccine, as set forth in the Agreement. The Company has agreed to pay the EDB
a royalty based on annual net sales of the vaccine in markets or jurisdictions outside of Singapore.

The foregoing is only a summary of the
material terms of the Grant, does not purport to be a complete description of the rights and obligations of the parties thereunder
and is qualified in its entirety by reference to the Grant that will be filed as an exhibit to the Company’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2019.

(d) Exhibits.

Exhibit No. | Description of Exhibit
99.1 | Press Release dated March 4, 2020

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: March 4, 2020
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2020-03-04_0001193805-20-000295.htm

Size

17,482 bytes

SHA-256

56a2c0920d00119e413779fb5749067a44fced60d80b3f8d8322e94e04d21f76

Our copy

SEC_ARCT_8-K_filed2020-03-04_0001193805-20-000295.htm

Original

www.sec.gov